Clinical trials: CYP2C19 Poor
CYP2C19 Poor, Extensive Metabolizers
Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin
The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.
- Trial name
- NCT00766025
- Testing
- Rosuvastatin Calcium
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole
The family of cytochrome P450 (CYP) is the most important drug metabolizing enzymes which contributes to the metabolism of a large proportion of drugs in humans.
- Trial name
- NCT03092193
- Testing
- Naproxen, Naproxen-esomeprazole
- Where
- Brazil
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Healthy
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
The objective of the current study is to evaluate the effect of once daily itraconazole on the pharmacokinetics of BI 409306 in poor (PM) and extensive metabolisers (EM) of CYP2C19.
- Trial name
- NCT02248259
- Testing
- BI 409306, Itraconazole
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM
A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers
- Trial name
- NCT02906176
- Testing
- Vfend (voriconazole) intravenous infusion, Vfend (voriconazole) tablet
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype
To assess the PK and safety profiles of ARQ 197 in extensive and poor metabolizers, as defined by CYP 2C19 genotype
- Trial name
- NCT00651638
- Testing
- Treatment with ARQ 197
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Pharmacogenomic Drug Interaction, Side Effect of Drug
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed…
- Conditions
- Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related
- Trial name
- PREPARE-Mayo (NCT06322238)
- Testing
- PGx panel test
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic